HanX Biopharmaceuticals
3378.HKWuhan, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile3378.HK · Stock Price
HKD 28.48-1.86 (-6.13%)
Market Cap: $493.1M
Historical price data
Overview
Clinical-stage Chinese biotech developing novel antibody therapies for oncology and immunology with multiple IND approvals.
OncologyImmunology
Technology Platform
Proprietary antibody engineering platforms focused on immune checkpoint modulation and novel antibody discovery.
Opportunities
Large Chinese oncology market expansion, novel combination therapies in TNBC, and potential for out-licensing novel antibody candidates to global partners.
Risk Factors
Intense competition in PD-1/immuno-oncology space, clinical differentiation challenges, regulatory hurdles in multiple jurisdictions, and dependence on partnership success.
Competitive Landscape
Competes with Chinese immuno-oncology leaders like BeiGene, Innovent, and Junshi in crowded PD-1 space; differentiation through novel antibody engineering and combination approaches.